Quick Answer
Euflexxa denials are increasingly common, particularly from commercial insurers that have tightened viscosupplementation coverage criteria. However, Euflexxa has a unique advantage in appeals: it is the only non-avian-sourced HA product on the market, making it medically necessary for patients with avian allergies. This guide explains how to build a strong appeal.
Why Euflexxa Injections Get Denied
Euflexxa (1% sodium hyaluronate) is manufactured by Ferring Pharmaceuticals using a bacterial fermentation process rather than rooster comb extraction. Despite being FDA-approved for knee osteoarthritis, denials happen for several reasons.
1. Medical Necessity Not Established
The most common denial reason. Your insurer determined that the submitted documentation did not sufficiently demonstrate that viscosupplementation is medically necessary for your condition. This often means that functional limitations were not clearly described or that the severity of your osteoarthritis was not well documented.
2. Conservative Treatment Failure Not Documented
Insurers require evidence of 3 or more months of failed conservative therapy. This includes physical therapy (with specific dates and number of sessions), oral pain medications (with names, dosages, and duration), and activity modification. Vague statements like “patient tried NSAIDs” without specifics trigger denials.
3. Incomplete Injection Series
Euflexxa is administered as a series of 3 weekly injections. Some insurers deny claims when patients do not complete the full series, or when the injections are not spaced at the recommended weekly intervals. If you missed an appointment, this can complicate your claim.
4. Plan Prefers a Different HA Product
Some insurers have preferred product lists and may deny Euflexxa in favor of a lower-cost alternative. In these cases, your appeal should focus on why Euflexxa is specifically necessary for you (e.g., avian allergy, prior success with Euflexxa, or intolerance of other products).
5. Prior Authorization Missing or Expired
If your plan requires prior authorization and it was not obtained before the first injection, all three injections in the series may be denied. Some plans also deny if PA was obtained but expired before the series was completed.
Euflexxa’s Non-Avian Advantage
Euflexxa is the only FDA-approved HA injection derived from bacterial fermentation rather than rooster combs. If you have an allergy to avian products (poultry, feathers, eggs), this is a strong medical necessity argument that can strengthen your appeal significantly.
Step-by-Step Appeal Process
Step 1: Review Your Denial Letter
Read the denial carefully to identify the exact reason code or explanation. Note the appeal deadline, which is typically printed near the bottom of the letter. If the denial reason is unclear, call the number on the letter and ask for a plain-language explanation. Request a copy of the plan’s medical policy for viscosupplementation.
Step 2: Gather Supporting Documentation
Work with your provider’s office to collect:
- Imaging reports: X-rays or MRI showing osteoarthritis of the knee (joint space narrowing, osteophytes, sclerosis)
- Conservative treatment records: Dated physical therapy notes, medication prescriptions and pharmacy records, cortisone injection records with dates and outcomes
- Functional assessment documentation: WOMAC scores, VAS pain scales, or detailed provider notes about daily activity limitations
- Allergy documentation (if applicable): If you have a documented avian allergy, include allergy test results or physician documentation, as this makes Euflexxa medically necessary over avian-sourced alternatives
- Prior Euflexxa success: If you have received Euflexxa before, include records showing duration and degree of relief
Step 3: Write Your Appeal Letter
Your appeal letter should address each denial reason point by point. Include both a personal statement and ask your physician for a separate letter of medical necessity. See the template below for guidance.
Step 4: Submit and Follow Up
Submit via your plan’s preferred channel (portal, fax, or certified mail). Retain copies of everything you send. Call 5 business days after submission to confirm receipt. Follow up weekly. If your plan has a peer-to-peer review option, ask your physician to participate, as speaking directly with the plan’s medical reviewer often helps.
Step 5: External Review Options
If your internal appeal is denied:
- Commercial plans: File for independent external review through your state insurance department. The external reviewer is independent of your insurer and the decision is typically binding.
- Medicare Advantage: Appeal to the Independent Review Entity (IRE). If denied again, you can request a hearing with an Administrative Law Judge (ALJ).
- Original Medicare: Request a redetermination, followed by a QIC reconsideration if needed.
Sample Appeal Letter Template
[Your Name] [Your Address] [City, State, ZIP] [Date]
[Insurance Company Name] [Appeals Department Address] [City, State, ZIP]
RE: Appeal of Denial — Euflexxa (sodium hyaluronate) Injection Series Member ID: [Your Member ID] Claim Number: [Claim Number from Denial Letter] Date of Service: [Dates of Injections] Patient: [Your Name, DOB]
Dear Appeals Committee:
I am writing to appeal the denial of coverage for my Euflexxa injection series for [left/right] knee osteoarthritis, denied on [denial date] for the reason stated as “[exact denial reason from letter].”
Diagnosis: I have osteoarthritis of the [left/right] knee (ICD-10: [M17.11 or M17.12]), confirmed by X-ray on [date] showing [describe findings].
Why Euflexxa Specifically: [If applicable: I have a documented allergy to avian/poultry products, making avian-sourced HA products (Synvisc-One, Supartz, Hyalgan, Orthovisc) medically contraindicated. Euflexxa is the only non-avian HA option available.] [If applicable: I have previously received Euflexxa with [X months] of significant pain relief, making it the most appropriate product for retreatment.]
Conservative Treatment History:
- Physical therapy: [number] sessions from [start date] to [end date]. Result: [limited improvement described].
- NSAIDs: [medication] [dosage] from [start date] to [end date]. Result: [inadequate relief or side effects].
- Cortisone injection: [date]. Result: [short-term relief of only X weeks].
- Activity modification: [describe weight management, exercise changes, assistive device use].
Functional Impact: My knee pain prevents me from [specific activities: walking more than X blocks, climbing stairs, sleeping without pain, performing work duties].
I respectfully request reversal of this denial. Enclosed are supporting medical records, imaging reports, and a letter of medical necessity from my physician.
Sincerely, [Your Signature] [Your Printed Name] [Phone Number]
Enclosures: Denial letter, medical records, X-ray report, physician letter, allergy documentation (if applicable), conservative treatment records
CPT and HCPCS Codes for Euflexxa
| Code Type | Code | Description |
|---|---|---|
| HCPCS (Product) | J7323 | Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose |
| CPT (Injection) | 20610 | Arthrocentesis, aspiration and/or injection of major joint (without ultrasound) |
| CPT (Injection w/ imaging) | 20611 | Arthrocentesis with ultrasound guidance |
| ICD-10 (Diagnosis) | M17.0 | Bilateral primary osteoarthritis of knee |
| ICD-10 (Diagnosis) | M17.11 | Primary osteoarthritis, right knee |
| ICD-10 (Diagnosis) | M17.12 | Primary osteoarthritis, left knee |
| Office Visit | 99213/99214 | Established patient office visit (if billed same day) |
Coding Note for Euflexxa
Euflexxa uses J7323, which is specific to this product. Each of the 3 injections in a series should be billed separately with J7323. Make sure your provider does not use a generic viscosupplementation code. Each injection is 2 mL (20 mg sodium hyaluronate).
Euflexxa-Specific Coverage Facts
About Euflexxa
- Manufacturer: Ferring Pharmaceuticals
- Active ingredient: 1% sodium hyaluronate (non-cross-linked)
- Molecular weight: Medium (2.4-3.6 million Daltons)
- Injection schedule: 3 weekly injections (2 mL each)
- FDA approved: Yes, for knee osteoarthritis
- Source: Bacterial fermentation (non-avian) — the only non-avian HA product
Medicare Coverage
Original Medicare Part B covers Euflexxa for knee osteoarthritis. Patients pay 20% coinsurance after the Part B deductible ($257 in 2026). Prior authorization is generally not required under Original Medicare. Medicare Advantage plans may require PA and may have preferred product lists.
Commercial Insurance Coverage
Commercial coverage for Euflexxa varies:
- Many plans cover it with prior authorization
- Some plans have tiered preferences, placing lower-cost HA products first
- Avian allergy documentation can override preferred product requirements
- Step therapy typically requires failed cortisone and/or a different HA brand
Common LCD Requirements
LCD policies for viscosupplementation generally require:
- Kellgren-Lawrence grade 2-3 osteoarthritis on X-ray (grade 4 bone-on-bone may reduce expected benefit)
- Failure of at least 3 months of conservative therapy
- Minimum 6-month interval between injection series
- Treatment limited to knee joint
Tips to Prevent Future Denials
- Complete the full 3-injection series on the recommended weekly schedule. Missed or delayed injections can trigger denials.
- Document avian allergy if you have one. This is your strongest argument for Euflexxa specifically over other HA products.
- Get prior authorization before the first injection in the series, and confirm the PA covers all 3 injections.
- Verify J7323 is used on billing. The wrong J-code is a common and easily preventable denial reason.
- Keep a pain diary between conservative treatment and your injection. Documenting daily pain levels strengthens medical necessity arguments.
- Schedule all 3 injections upfront to avoid gaps in the series that could be questioned by the insurer.
- Use correct ICD-10 codes: M17.11 (right knee), M17.12 (left knee), M17.0 (bilateral).
Frequently Asked Questions
How long does a Euflexxa appeal take?
Internal appeals typically take 30 days for both commercial and Medicare Advantage plans. Expedited appeals for urgent cases can be decided within 72 hours. If you need to pursue an external review after a denied internal appeal, add another 30-60 days. Plan for 6-12 weeks total.
What is the success rate for Euflexxa appeals?
Success rates depend heavily on documentation quality. Appeals that include complete conservative treatment records, current imaging, a physician letter of medical necessity, and (when applicable) avian allergy documentation tend to have higher success rates. Industry data suggests 40-60% of well-documented viscosupplementation appeals are overturned.
Can my doctor help with the appeal?
Absolutely. Your physician’s letter of medical necessity is often the deciding factor. Ask your doctor to specifically address each denial reason, explain why Euflexxa (rather than another HA product) is appropriate, and describe your functional limitations in detail. Some plans offer a peer-to-peer review where your doctor speaks directly with the plan’s medical reviewer.
What if my second appeal is denied?
You have the right to an independent external review. For commercial plans, your state insurance department coordinates this review. For Medicare, it goes to an Independent Review Entity. External reviews are conducted by physicians who are not employed by your insurer, and they overturn denials in a meaningful percentage of cases.
Why would my plan prefer a different HA brand over Euflexxa?
Insurers negotiate pricing with manufacturers. Some plans get better pricing on certain brands and create preferred product lists. If your plan prefers a different brand, you can request a formulary exception. Valid reasons include avian allergy, prior treatment success with Euflexxa, or adverse reaction to the preferred product.